Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung cancer.
A TRANSPLANT recipient has died of cancer after contracting the illness from his organ donor. The unnamed patient, 69, from Arizona underwent an organ transplant to treat his liver ...
Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...
Johnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival ...
The FDA previously designated the ADC as a breakthrough drug for relapsed or refractory extensive-stage small-cell lung ...
Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...
Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...
Medical advancements make early-detected cancers more manageable and treatable, with immunotherapy and CAR T cell therapy ...
The brother of AFL WAG Kellie Finlayson was allegedly coward punched before being rushed to hospital on Saturday evening in Port Lincoln, South Australia.
Panelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient ...